Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
.webp)
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Lumakras / Lumykras (sotorasib) is a small-molecule KRAS G12C inhibitor—the first and only targeted therapy designed to specifically inhibit oncogenic KRAS G12C mutations. It is indicated for
KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy.
KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC): In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
KRAS is one of the most frequently mutated genes in human cancers, and KRAS G12C mutations occur in approximately 10–13% of patients with non-small cell lung cancer, particularly in adenocarcinoma histology and in patients with a smoking history. For decades, KRAS mutations were considered undruggable, but sotorasib represents a breakthrough therapeutic approach. By selectively binding to KRAS G12C-mutant proteins, sotorasib irreversibly traps the protein in its inactive GDP-bound state, preventing downstream signaling activation and cancer cell proliferation. This mechanism-based inhibition reduces tumor growth, induces apoptosis in cancer cells, and improves progression-free and overall survival in KRAS G12C-mutant NSCLC.
Lumakras / Lumykras is designed for patients with confirmed KRAS G12C mutations who have progressed on at least one prior systemic therapy (chemotherapy, immunotherapy, or targeted therapy). Molecular testing to confirm KRAS G12C mutation status is essential before initiating treatment.
It is a prescription anticancer medicine and must be used under the supervision of a qualified medical oncologist or pulmonologist experienced in targeted oncology.
Sotorasib may increase liver enzymes and rarely cause severe liver damage. Regular liver function tests are recommended, especially during the first three months. Seek immediate medical attention for jaundice, dark urine, pale stools, severe fatigue, or abdominal pain.
Sotorasib may cause heart failure or reduced left ventricular ejection fraction (LVEF). A baseline cardiac evaluation, such as an echocardiogram or MUGA scan, with periodic monitoring during treatment is recommended, particularly for patients with cardiovascular risk factors.
Rash is a common side effect of Sotorasib. Rare but serious skin reactions, including Stevens-Johnson Syndrome (SJS) and DRESS syndrome, have occurred. Report any new, severe, or worsening rash immediately for prompt medical evaluation and treatment.
Sotorasib may increase the risk of serious infections. Patients should promptly report symptoms such as fever, chills, persistent cough, sore throat, or other signs of infection so that appropriate medical evaluation and treatment can begin without delay.
Muscle pain, joint pain, myositis, and fasciitis have been reported during Sotorasib treatment. Severe symptoms may require temporary treatment interruption or permanent discontinuation. Inform your healthcare provider about any persistent pain, weakness, or stiffness.
Sotorasib may harm an unborn baby. Women of reproductive potential should use effective contraception during treatment and for at least one week after the final dose. Breastfeeding is not recommended while receiving this medicine.
Sotorasib is metabolized by CYP3A4 and may interact with strong CYP3A4 inhibitors or inducers. Inform your physician about all prescription medicines, over-the-counter drugs, vitamins, and herbal supplements before starting or during treatment.
Patients with moderate-to-severe hepatic impairment may require dose adjustments when taking Sotorasib. Use the medicine cautiously in individuals with impaired kidney function, and follow your physician's recommendations regarding monitoring and treatment modifications.
Take Sotorasib exactly as prescribed and at the same time each day to maintain therapeutic effectiveness. Do not skip, increase, or reduce the dose without consulting your oncologist, even if you feel better or experience side effects.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details and KRAS G12C mutation confirmation to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability, reviews KRAS G12C mutation status, and confirms eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-monitored import & handling: The medicine is sourced and transported under strict pharmaceutical compliance conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Access This Process Easily via Our App:
You can manage the entire process seamlessly through the Named Patient Program App, available on both the Play Store and App Store.
Track your medicine request in real-time
Upload documents and approvals
View quotations and timelines
Get status updates at every step
You can also access detailed information by clicking Login in the website header.
On mobile, open the hamburger menu (☰) and tap Login from the dropdown to get started.
LUMAKRAS / LUMYKRAS (sotorasib) tablets may be imported in the patient's name only, by patients or government hospitals. The following documentation is required:
A valid prescription from a qualified medical oncologist or pulmonologist
The patient's diagnostic reports (including biopsy confirmation, KRAS G12C mutation testing, baseline liver and cardiac function assessment)
Patient ID proof (issued by the Government of India)
The order is confirmed only after receipt and verification of a valid prescription from the oncologist, KRAS G12C mutation confirmation, and an import permit, if applicable.
LUMAKRAS / LUMYKRAS (sotorasib tablets) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Lumakras / Lumykras is not commercially marketed in India.
However, patients in India can legally access LUMAKRAS / LUMYKRAS through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.
NamedPatientProgram.com (NPP) acts as a facilitator under named patient supply, providing input on:
Availability of Lumakras / Lumykras in India and pathways to access it
Availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE)
Lumakras / Lumykras price in India under the NPP route
Sourcing from genuine, reliable channels in the USA, Europe, Singapore, Canada, and Australia
KRAS G12C mutation testing support and confirmation guidance
Ensuring full transparency throughout the process
LUMAKRAS / LUMYKRAS can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only upon receipt of a valid doctor's prescription and, where applicable, an import permit.
Named Patien tProgram.com (NPP) can source Lumakras / Lumykras from reliable global manufacturers and qualified pharmaceutical supply channels and facilitate supply to patients, doctors, and hospitals under applicable legal provisions. Lumakras / Lumykras tablets are stable at room temperature and shipped via standard pharmaceutical logistics.
All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For Lumakras / Lumykras cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Mumbai: As a major oncology hub with leading cancer institutes like Tata Memorial, Mumbai sees high demand for advanced targeted therapies like Lumakras / Lumykras. Access is coordinated for patients with KRAS G12C-mutant NSCLC requiring breakthrough targeted treatment.
Bangalore: With a growing network of multispecialty hospitals and dedicated oncology centres, Bangalore supports access to global precision oncology treatments through structured import pathways guided by treating specialists.
Delhi: As part of the Delhi NCR region, the city has a strong concentration of cancer centers and pulmonary oncologists, making it a key location for accessing advanced imported targeted therapies.
Gurgaon: Home to leading hospitals like Medanta and other super-specialty centers, Gurgaon plays an important role in facilitating access to innovative cancer treatments through coordinated care pathways.
Noida: With proximity to Delhi and access to top cancer hospitals, Noida patients benefit from streamlined logistics and specialist-driven treatment planning for precision oncology.
Hyderabad: Hyderabad's advanced healthcare infrastructure and oncology expertise support patients seeking access to internationally approved targeted cancer therapies.
Chennai: Known for its established medical ecosystem and pulmonary oncology expertise, Chennai attracts patients from across India for complex NSCLC treatments and specialized drug access.
Kolkata: A key eastern healthcare hub, Kolkata offers access to advanced oncology care through leading hospitals and lung cancer treatment centers.
Ahmedabad: Ahmedabad's expanding healthcare sector and oncology facilities support patients requiring advanced and imported targeted cancer therapies.
Pune: With reputed hospitals and growing pulmonary oncology infrastructure, Pune is an emerging center for access to specialized NSCLC treatments.
Chandigarh: Serving North India, Chandigarh provides access to advanced medical care through reputed institutions and specialist-led precision oncology treatment planning.
Jaipur: Jaipur's improving healthcare network enables patients to explore access to innovative targeted cancer therapies through structured import processes.
Lucknow: As a major city in North India, Lucknow supports access to advanced oncology treatments through both public and private healthcare institutions.
Indore: Indore is emerging as a regional healthcare hub, offering access to specialized cancer care and modern precision medicine treatment pathways.
Bhopal: Patients in Bhopal can access advanced cancer treatments through the growing healthcare infrastructure and oncology referral networks.
Nagpur: Nagpur serves as a central hub for patients across Vidarbha, with increasing access to oncology care and targeted cancer therapies.
Surat: Surat's developing healthcare ecosystem supports patients seeking access to global precision oncology treatments through coordinated care.
Patna: As a major city in Eastern India, Patna provides growing access to advanced cancer treatment through expanding hospital networks.
Coimbatore: Coimbatore is known for quality healthcare services, offering access to advanced oncology treatments in South India.
Kochi: With modern hospitals and specialist pulmonary oncology care, Kochi enables patients to explore access to internationally approved targeted cancer therapies.
Note: Access timelines may vary depending on documentation, KRAS mutation confirmation, regulatory approvals, and sourcing logistics.
Lumakras / Lumykras is used in advanced pulmonary oncology settings for patients with KRAS G12C-mutant NSCLC and can be accessed at leading hospitals across India, where specialists guide treatment decisions and coordinate patient-specific access pathways.
Major Hospitals Covered:
Tata Memorial Centre: One of India's premier cancer institutes, Tata Memorial plays a key role in treating complex lung cancer cases and guiding patients toward advanced targeted therapies like Lumakras / Lumykras.
AIIMS: As a leading government medical institution, AIIMS provides comprehensive cancer care and supports patients requiring access to specialized and emerging precision oncology treatments.
Apollo Hospitals: With a nationwide presence and strong pulmonary oncology programs, Apollo Hospitals offers advanced targeted therapy services and facilitates access to global treatment options through its extensive medical network.
Fortis Healthcare: Fortis hospitals are equipped with modern cancer care facilities and multidisciplinary oncology teams that manage complex targeted treatment pathways for patients.
Max Healthcare: Max Healthcare is known for its strong oncology and pulmonary oncology departments, providing access to innovative targeted therapies under expert clinical supervision.
Manipal Hospitals: Manipal Hospitals supports advanced precision oncology care through experienced specialists and structured treatment planning across multiple cities.
Kokilaben Dhirubhai Ambani Hospital: A leading private hospital in Mumbai, Kokilaben Hospital offers cutting-edge oncology care and access to advanced global targeted therapies.
Medanta – The Medicity: Medanta is a renowned super-specialty hospital where complex lung cancer cases are managed with advanced targeted treatment protocols and global access support.
BLK-Max Super Speciality Hospital: BLK-Max provides comprehensive oncology services and supports patients seeking access to specialized precision medicine treatment options.
Rajiv Gandhi Cancer Institute: A dedicated cancer care center, RGCI focuses on advanced oncology treatments and supports patients through complex targeted therapy journeys.
HCG Cancer Centre: HCG is a specialized cancer hospital network known for its focus on precision oncology and advanced targeted treatment modalities.
Narayana Health: Narayana Health combines affordability with advanced medical care, offering precision oncology services across multiple locations in India.
Amrita Hospital: Amrita Hospital provides high-quality cancer care with a focus on patient-centric targeted therapy and access to modern precision treatments.
Yashoda Hospitals: Yashoda Hospitals are known for their strong oncology departments and advanced targeted therapy infrastructure in South India.
Aster Hospitals: Aster Hospitals offer integrated cancer care services and support access to innovative targeted therapies through coordinated treatment planning.
Sir Ganga Ram Hospital: A well-established hospital in Delhi, Sir Ganga Ram provides multidisciplinary oncology care supported by experienced pulmonary oncology specialists.
Jaslok Hospital: Jaslok Hospital is known for its specialized medical services and advanced precision oncology treatment capabilities.
Ruby Hall Clinic: Ruby Hall Clinic offers comprehensive cancer care and supports patients requiring advanced and imported targeted therapies.
CARE Hospitals: CARE Hospitals provide modern precision oncology treatment facilities and multidisciplinary care across multiple cities.
Global Hospitals: Global Hospitals are equipped with advanced medical technologies and precision oncology expertise to manage complex lung cancer cases.
Note: Lumakras / Lumykras is not stocked for direct purchase but is arranged through compliant import processes and delivered to the hospital for patient-specific treatment.
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
